维普中文期刊产品整合服务
27篇 您的检索式:作者名="Delord JP"
    题名 作者 年代 出处 被引量
1A phase Ⅰ dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first- line chemotherapy for metastatic breast cancer显示文摘Delord JP Dalenc F Pinguet F 2007Oncology2007,72,56:1
2HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum显示文摘Perez-Soler R Delord JP Halpern A 2005Oncologist2005,10,5:1
3Population pharmacokinetics of oxaliplatin 显示文摘Delord JP Umlil A Guimbaud R 2003Cancer Chemother Pharmacol2003,51,2:1
4Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer显示文摘Delord JP Bennouna J Artru P 2007Br J Cancer2007,97,3:1
5HER1/EGFRinhibitor-associated rash: futuredi rections for managementand investigation out comes from the HER1/ EGFR inhibitorrash management forum 显示文摘Perez-Soler R Delord JP Halpem A 2005Oncologist2005,10,5:1
6Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease - free survival in a micrometastasis model of ovarian carcinoma 显示文摘Delord JP Allal C Canal M 2005Ann Oncol2005,16,12:1
7Selective inhibition of HER2 inhibits AKT signal tranaductiou and prolongs disease-free survival in a micromctastanis model of ovarian carcinoma显示文摘Delord JP Alial C Canal M 2005Ann Oncol2005,16,:1
8A phase 1b dose-escalation trial of erlotinib,capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients显示文摘Delord JP Beale P Van Cutsem E 2004J Clin Oncol ASCO Meeting Abstracts2004,22,:1
9Combination chemotherapy of vinorelbine and cisplatin : a phase I pharmacokinetic study in pa- tients with metastatic solid tumors 显示文摘Delord JP Puozzo C Lefresne F 2009Anticancer Res2009,29,2:1
10Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation显示文摘Balin-Gauthier D Delord JP Pillaire M J 0,,:1
11In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR 显示文摘BALIN-GAUTHIER D DELORD JP ROCHAIX P 2006Cancer Chemother Pharmacol2006,57,6:1
12Cetuximab poten- tiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation 显示文摘Balin - Gauthier D Delord JP Pillaire M J 2008Br J Cancer2008,98,1:1
13Phase Ⅱ study of UFT with leucovorin and irinotecan ( TEGAFIRI ): first-line therapy for metastatic colorectal cancer 显示文摘Delord JP Bennouna J Artry P 2007Br J Cancer2007,97,3:1
14In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR显示文摘Balin-Gauthier D Delord JP Rochaix P et cd 2006Cancer Chem Pharmacol2006,57,6:1
15HER1/EGFR inhibitor-associated rash:future directions for management and investigation outcomes from the HER1/EGFR inhibi- tor rash management forum 显示文摘Perez-Soler R Delord JP Halpern A 2005Oncologist2005,10,5:1
16HER1/EGFR inhibitor-associated rash: future directions for management and investigation outeomes from the HER1/EGFR inhibitor rash management forum 显示文摘Perez-Soler R Delord JP Halpern A 2005Oncologist2005,10,5:1
17Cetuximab potenti-ates oxaliplatin cytotoxic effect through a defect in NER and DNAreplication initiation显示文摘Balin-Gauthier D Delord JP Pillaire MJ 2008Br J Cancer2008,98,1:1
18Cetuximab potentiatesoxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation显示文摘Balin-Gauthier D Delord JP 2008Br J Cancer2008,98,1:1
19HER1/ EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum显示文摘Perez-Soler R Delord JP Halpem A 2005Oncologist2005,10,5:1
20HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum显示文摘Perez-Soler R Delord JP Halpem A 2005Oncologist2005,10,5:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费